Mannosidase Deficiency Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major mannosidase deficiency diseases markets are expected to exhibit a CAGR of 11.72% during 2024-2034.
The mannosidase deficiency diseases market has been comprehensively analyzed in IMARC's new report titled "Mannosidase Deficiency Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mannosidase deficiency diseases, also known as mannosidosis, encompass a group of uncommon inherited metabolic disorders characterized by the deficiency of the enzyme alpha-D-mannosidase. This enzyme plays an essential part in breaking down complex sugars called mannose-containing oligosaccharides within cells. The deficiency leads to the accumulation of these undegraded substances, causing cellular dysfunction and impacting various organs. The symptoms of these ailments can vary widely but often include developmental delays, intellectual disabilities, skeletal abnormalities, and facial coarseness. Individuals suffering from mannosidase deficiency diseases might also experience impaired motor skills, muscle weakness, hearing and vision problems, and a decline in overall cognitive function. Additional signs can involve recurrent infections, an enlarged liver and spleen, and behavioral changes. Diagnosing these conditions involves clinical evaluation, genetic testing, and biochemical assessments. Measuring the levels of alpha-D-mannosidase activity in blood or various other tissues can help to confirm the deficiency. Molecular genetic testing aids in identifying specific gene mutations responsible for the condition.
The increasing prevalence of mutations in genes responsible for the production of mannosidase enzymes, chiefly the MAN2B1 and MANBA genes, is primarily driving the mannosidase deficiency diseases market. In addition to this, the inflating utilization of supportive measures, including physical and occupational therapies, owing to their role in enhancing motor skills, improving mobility, and optimizing overall quality of life for patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective therapeutic interventions, encompassing enzyme replacement therapies, substrate reduction approaches, and molecular chaperone treatments, is further bolstering the market growth. These regimens aim to ameliorate enzyme deficiency and alleviate disease symptoms, contributing to better treatment outcomes. Apart from this, the rising awareness and improved diagnostic techniques, including high-throughput sequencing and specialized biochemical assays, since they help in earlier and more accurate diagnoses, thereby facilitating prompt initiation of treatment protocols, are acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene-editing techniques like CRISPR-Cas9, which work by introducing corrected gene sequences into patient cells to rectify the underlying enzymatic deficiency at the genetic level and offer a permanent cure, is expected to drive the mannosidase deficiency diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mannosidase deficiency diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mannosidase deficiency diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mannosidase deficiency diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mannosidase deficiency diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mannosidase deficiency diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mannosidase deficiency diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the mannosidase deficiency diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mannosidase deficiency diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mannosidase deficiency diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mannosidase deficiency diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of mannosidase deficiency diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mannosidase deficiency diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mannosidase deficiency diseases across the seven major markets?
What is the size of the mannosidase deficiency diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mannosidase deficiency diseases?
What will be the growth rate of patients across the seven major markets?
Mannosidase Deficiency Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mannosidase deficiency diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mannosidase deficiency diseases market?
What are the key regulatory events related to the mannosidase deficiency diseases market?
What is the structure of clinical trial landscape by status related to the mannosidase deficiency diseases market?
What is the structure of clinical trial landscape by phase related to the mannosidase deficiency diseases market?
What is the structure of clinical trial landscape by route of administration related to the mannosidase deficiency diseases market?
The mannosidase deficiency diseases market has been comprehensively analyzed in IMARC's new report titled "Mannosidase Deficiency Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mannosidase deficiency diseases, also known as mannosidosis, encompass a group of uncommon inherited metabolic disorders characterized by the deficiency of the enzyme alpha-D-mannosidase. This enzyme plays an essential part in breaking down complex sugars called mannose-containing oligosaccharides within cells. The deficiency leads to the accumulation of these undegraded substances, causing cellular dysfunction and impacting various organs. The symptoms of these ailments can vary widely but often include developmental delays, intellectual disabilities, skeletal abnormalities, and facial coarseness. Individuals suffering from mannosidase deficiency diseases might also experience impaired motor skills, muscle weakness, hearing and vision problems, and a decline in overall cognitive function. Additional signs can involve recurrent infections, an enlarged liver and spleen, and behavioral changes. Diagnosing these conditions involves clinical evaluation, genetic testing, and biochemical assessments. Measuring the levels of alpha-D-mannosidase activity in blood or various other tissues can help to confirm the deficiency. Molecular genetic testing aids in identifying specific gene mutations responsible for the condition.
The increasing prevalence of mutations in genes responsible for the production of mannosidase enzymes, chiefly the MAN2B1 and MANBA genes, is primarily driving the mannosidase deficiency diseases market. In addition to this, the inflating utilization of supportive measures, including physical and occupational therapies, owing to their role in enhancing motor skills, improving mobility, and optimizing overall quality of life for patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective therapeutic interventions, encompassing enzyme replacement therapies, substrate reduction approaches, and molecular chaperone treatments, is further bolstering the market growth. These regimens aim to ameliorate enzyme deficiency and alleviate disease symptoms, contributing to better treatment outcomes. Apart from this, the rising awareness and improved diagnostic techniques, including high-throughput sequencing and specialized biochemical assays, since they help in earlier and more accurate diagnoses, thereby facilitating prompt initiation of treatment protocols, are acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene-editing techniques like CRISPR-Cas9, which work by introducing corrected gene sequences into patient cells to rectify the underlying enzymatic deficiency at the genetic level and offer a permanent cure, is expected to drive the mannosidase deficiency diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the mannosidase deficiency diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mannosidase deficiency diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mannosidase deficiency diseases market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mannosidase deficiency diseases market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mannosidase deficiency diseases market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mannosidase deficiency diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the mannosidase deficiency diseases market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the mannosidase deficiency diseases market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the mannosidase deficiency diseases market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of mannosidase deficiency diseases across the seven major markets?
What is the number of prevalent cases (2018-2034) of mannosidase deficiency diseases by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of mannosidase deficiency diseases by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with mannosidase deficiency diseases across the seven major markets?
What is the size of the mannosidase deficiency diseases patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of mannosidase deficiency diseases?
What will be the growth rate of patients across the seven major markets?
Mannosidase Deficiency Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for mannosidase deficiency diseases drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mannosidase deficiency diseases market?
What are the key regulatory events related to the mannosidase deficiency diseases market?
What is the structure of clinical trial landscape by status related to the mannosidase deficiency diseases market?
What is the structure of clinical trial landscape by phase related to the mannosidase deficiency diseases market?
What is the structure of clinical trial landscape by route of administration related to the mannosidase deficiency diseases market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MANNOSIDASE DEFICIENCY DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MANNOSIDASE DEFICIENCY DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MANNOSIDASE DEFICIENCY DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MANNOSIDASE DEFICIENCY DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MANNOSIDASE DEFICIENCY DISEASES - UNMET NEEDS
10 MANNOSIDASE DEFICIENCY DISEASES - KEY ENDPOINTS OF TREATMENT
11 MANNOSIDASE DEFICIENCY DISEASES - MARKETED PRODUCTS
11.1 List of Mannosidase Deficiency Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Lamzede (Velmanase Alfa-Tycv) - Chiesi Farmaceutici
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MANNOSIDASE DEFICIENCY DISEASES - PIPELINE DRUGS
12.1 List of Mannosidase Deficiency Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 MANNOSIDASE DEFICIENCY DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 MANNOSIDASE DEFICIENCY DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MANNOSIDASE DEFICIENCY DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mannosidase Deficiency Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mannosidase Deficiency Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mannosidase Deficiency Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mannosidase Deficiency Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mannosidase Deficiency Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mannosidase Deficiency Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mannosidase Deficiency Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mannosidase Deficiency Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
16 MANNOSIDASE DEFICIENCY DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MANNOSIDASE DEFICIENCY DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MANNOSIDASE DEFICIENCY DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MANNOSIDASE DEFICIENCY DISEASES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MANNOSIDASE DEFICIENCY DISEASES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MANNOSIDASE DEFICIENCY DISEASES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MANNOSIDASE DEFICIENCY DISEASES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MANNOSIDASE DEFICIENCY DISEASES - UNMET NEEDS
10 MANNOSIDASE DEFICIENCY DISEASES - KEY ENDPOINTS OF TREATMENT
11 MANNOSIDASE DEFICIENCY DISEASES - MARKETED PRODUCTS
11.1 List of Mannosidase Deficiency Diseases Marketed Drugs Across the Top 7 Markets
11.1.1 Lamzede (Velmanase Alfa-Tycv) - Chiesi Farmaceutici
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MANNOSIDASE DEFICIENCY DISEASES - PIPELINE DRUGS
12.1 List of Mannosidase Deficiency Diseases Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 MANNOSIDASE DEFICIENCY DISEASES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 MANNOSIDASE DEFICIENCY DISEASES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MANNOSIDASE DEFICIENCY DISEASES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Mannosidase Deficiency Diseases - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Mannosidase Deficiency Diseases - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Mannosidase Deficiency Diseases - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Mannosidase Deficiency Diseases - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Mannosidase Deficiency Diseases - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Mannosidase Deficiency Diseases - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Mannosidase Deficiency Diseases - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Mannosidase Deficiency Diseases - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Mannosidase Deficiency Diseases - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Mannosidase Deficiency Diseases - Access and Reimbursement Overview
16 MANNOSIDASE DEFICIENCY DISEASES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MANNOSIDASE DEFICIENCY DISEASES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MANNOSIDASE DEFICIENCY DISEASES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
